Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 13/20 | 0.47 |
| ▸ | VHL | P40337 | 4/20 | 0.42 |
| ▸ | ELOC | Q15369 | 3/20 | 0.42 |
| ▸ | ELOB | Q15370 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20425310 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL31040654 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL20425493 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL18551323 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL13318867 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL25339541 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL806127 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL30178517 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL29091282 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL8224728 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2024085699-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2024-04-25 | — | — | WO | disclosed |
| CN-117551089-A | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-110612297-B | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ATM 4174/4885ELANE 1237/4885VHL 1251/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ATM 2618/4885ELANE 3586/4885VHL 208/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ATM 1549/4885ELANE 2672/4885VHL 735/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ATM 4174/4885ELANE 1237/4885VHL 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.